CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Hansa Biopharma AB Company Snapshot
Hansa Biopharma AB operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Hansa Biopharma AB with three other companies in this sector in Sweden: Q linea AB (2018 sales of 1.07 million Swedish Kronor [US$114,968.10 ] ), Biovica International AB (2.72 million Swedish Kronor [US$293,675.55 ] ), and Diamyd Medical Ab (726,000.00 Swedish Kronor [US$78,299.10 ] ).

Sales Analysis. During the year ended December of 2018, sales at Hansa Biopharma AB were SEK 3.36 million (US$362.16 thousand). This is a decrease of 2.4% versus 2017, when the company's sales were SEK 3.44 million.
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Hansa Biopharma AB
  Stock Performance Chart for Hansa Biopharma AB
 
  Stock Data: Recent Stock Performance:
  Current Price (2/15/2019): 220.00
(Figures in Swedish Kronor)
1 Week -0.5%   13 Weeks -11.6%  
4 Weeks -20.9%   52 Weeks -15.0%  
 
Hansa Biopharma AB Key Data:
  Ticker: HNSA Country: Sweden
  Exchanges: STO Major Industry: Commercial Services & Supplies
    Sub Industry: Commercial Physical Research
  2018 Sales 3,358,000
(Year Ending Jan 2019).
Employees: 33
  Currency: Swedish Kronor Market Cap: 8,791,175,800
  Fiscal Yr Ends: December Shares Outstanding: 39,959,890
  Share Type: AKTIE Closely Held Shares: 9,681,715
 
 
Sponsored Links
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.